SCI时时刷

search
Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel
Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel
Analyzing the relationship between TPX2 and the clinicopathological features of NSCLC via bioinformatics analysis.
Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
Evaluating Elacestrant in the Management of ER-Positive, HER2-Negative Advanced Breast Cancer: Evidence to Date
In this review, we will analyze the rationale for the use of elacestrant, the currently available data regarding efficacy ...
Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer
Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer
This study investigated the role of several biomarkers in patients with leptomeningeal metastases from lung cancer to dete...
A Review of CAR-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore
A Review of CAR-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore
A review focused on the burden of relapsed/refractory paediatric B-ALL, limitations of strategies, emerging paradigms and ...
Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study
This study aimed to explore the efficacy and safety of immunotherapy retreatment in metastatic cervical cancer
Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect [Corrigendum]
Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Application Prospect [Corrigendum]
Corrigendum for the article Clinical Applications of Aneuploidies in Evolution of NSCLC Patients: Current Status and Appli...
Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
A 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy.
HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
This review describes the therapeutic landscape for HER2-positive advanced breast cancer (ABC) and evaluates its benefits ...
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward
In this article, we present recent reports on neoadjuvant PD-1/PD-L1 blockade therapy and discuss its future challenges.
Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report
Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK- LIMS1 Fusion: A Case Report
Case report of a 48-year-old male Chinese patient of advanced lung adenocarcinoma harboring a novel ALK-LIMS1 showed no re...
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Recurrent Glioblastoma: Ongoing Clinical Challenges and Future Prospects
Reviewing the currently available treatments, obstacles in the search for new treatments, and novel lines of research that...
Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report
Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma...
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
Adjuvant Therapy for High-Risk Localized Renal Cell Carcinoma: Current Landscape and Future Direction
Reviewing current body of evidence defining and phase III randomized clinical trials to assess safety and efficacy of thes...
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
Alectinib-Induced Severe Hemolytic Anemia in a Patient with ALK-Positive Non-Small Cell Lung Cancer: A Case Report
Drug-induced hemolytic anemia is a significant adverse event caused by alectinib treatment in a patient with ALK-positive ...
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
Post-Hematopoietic Cell Transplantation Relapsed Acute Lymphoblastic Leukemia: Current Challenges and Future Directions
Providing insight into use of cellular therapy in MRD positivity, decreasing donor chimerism, and modalities of combining ...
Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival
Overexpression of BCL2, BCL6, VEGFR1 and TWIST1 in Circulating Tumor Cells Derived from Patients with DLBCL Decreases Event-Free Survival
This study showed that in liquid biopsies analyzed, the presence of CTCs can be confirmed through molecular biomarkers, an...
Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
Combination Use of First-Line Afatinib and Proton-Pump Inhibitors Reduces Overall Survival Among Patients with EGFFR Mutant Lung Cancer
The pharmacological mechanism of Dangshen (Codonopsis pilosula) against hepatocellular carcinoma based on network pharmaco...
Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan
Therapeutic potential of sacituzumab govitecan using targeted therapy for locally advanced or metastatic urothelial cancer...
Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
Reviewing the data to date supporting the use of enfortumab vedotin for metastatic urothelial cancer treatment. Read more